

IMMUNOTHERAPY: MANAGING THE BREAKTHROUGH

HOT TOPICS AND MULTIDISCIPLINARY CHALLENGES IN TODAY'S CANCER PATIENT CARE

MEETING

PROGRAM

TIME	SESSION	SPEAKER(S)
16.00 - 16.30	<i>Arrivals and registration</i>	
16.30 - 16.45	Welcome and introduction	Dr V. Walsh (BMS) Prof P. Coulie, ISA chair (de Duve Institute, UCL)
16.45 - 17.20	Plenary Hot topics - Expert Panel Session moderated by Prof A. Awada (I.J. Bordet)	Prof P. Pauwels (UZ Antwerpen) Dr S. Aspeslagh (UZ Brussel) Dr S. Rauh (CHEM, Luxemburg)
17.20 - 17.25	<i>Transfer to workshop groups</i>	
17.25 - 18.05	Workshop series 1 A1. Cardio - Oncology OR B1. Managing patients with underlying autoimmune diseases	Prof G. Jerusalem (CHU Liège) Dr M. Moonen (CHU Liège) Prof B. Lauwerys (Cliniques St Luc - UCL) Prof K. Vermaelen (UZ Gent)
18.05 - 18.30	<i>Break</i>	
18.30 - 19.10	Workshop series 2 A2. The challenge of survivorship care in the field of immunotherapy moderated by Prof B. Neyns (UZ Brussel) OR B2. Use of CPI in patients with specific medical conditions and challenges raised by therapies	Dr A. Rogiers (UVC Brugmann-Site Horta) Prof A. Awada (I.J. Bordet) Prof J. Machiels (Cliniques St Luc - UCL)
19.10 - 19.15	<i>Transfer to workshop group</i>	
19.15 - 19.55	Workshop series 3 A3. Patient education moderated by Prof J. Vansteenkiste (UZ Leuven) OR B3. Managing immune related adverse events: focus on skin and endocrine system	Mrs M. Vandeveld & Mrs. A. Coolbrandt (UZ Leuven) Prof T. Kerre (UZ Gent) Dr S. Rauh (CHEM, Luxemburg) Dr S. Aspeslagh (UZ Brussel) Prof V. del Marmol (Erasmus Hospital)
19.55 - 20.00	<i>Transfer to plenary room</i>	
20.00 - 20.35	Plenary Hot topics - Expert Panel Session moderated by Prof E. Van Cutsem (UZ Leuven)	Prof R. Schots (UZ Brussel) Prof P. Coulie (de Duve Institute, UCL) Prof B. Neyns (UZ Brussel)
20.35 - 20.45	Closing remarks	Dr P. Lacante (BMS) Prof P. Coulie (de Duve Institute, UCL)
20.45 - 21.30	<i>Buffet (pre-registration)</i>	

REGISTER at www.isa18dec.be

Register now

IMMUNOTHERAPY: MANAGING THE BREAKTHROUGH

HOT TOPICS AND MULTIDISCIPLINARY CHALLENGES IN TODAY'S CANCER PATIENT CARE

MEETING

WORKSHOP SERIES

Besides the plenary sessions, you will be able to attend 1 workshop in the 3 series. When registering via www.isa18dec.be you will be asked to indicate in each workshop series, which one (A1 or B1 + A2 or B2 + A3 or B3) would be your preferred one to attend (first come-first serve)

Please find hereunder the Learning Objectives for each workshop

Workshop series 1 - 17.25-18.05

A1. Cardio - Oncology

- Immunotherapy in patients with history of cardio-vascular disease: Initial work-up and monitoring of patients.
- Acute cardiac toxicity (myocarditis, pericarditis): Challenges in diagnosis and treatment
- Continuation of immunotherapy after cardiovascular side effects indications and patient monitoring

.....

B1. Managing patients with underlying autoimmune disease

- Pathophysiology underlying the development of immune-related adverse events (irAEs) under immune checkpoint inhibition
- Risk assessment of developing severe irAEs in patients with pre-existing auto-immune disease
- Potential clinical or biological biomarkers that could predict the risk of developing irAEs

Workshop series 2 - 18.30-19.10

A2. The challenge of survivorship care in the field of immunotherapy

- Presentation of the first results of psycho-social outcome in metastatic melanoma survivors treated with immune checkpoint inhibitors.
- The challenge of identifying patients who need referral to mental health care.
- What about cognitive disturbances and possible treatment interventions?

.....

B2. Use of immune checkpoint inhibitors in patients with specific medical conditions and challenges raised by therapies

- Can CPI treatment be considered as an option in patients with cancer and solid organ transplant?
- An update on use of CPI in elderly and in patients with brain metastases, Hep B and HIV
- Can Flu vaccine be given to patients receiving CPI ?
- Hyperprogression: truth or hype? What to know about pseudoprogression?

Workshop series 3 - 19.15-19.55

A3. Patient education

- How can effective patient education about immunotherapy (mechanism of action, prospects, possible side effects) be provided before the start of treatment?
- How does the patient monitor symptoms during treatment and for which ones is contact with the hospital team needed, in order to allow early detection of potentially serious adverse events?
- How does the treatment team (physician, nurse, oncocoach) capture and respond to patients' signals of potentially serious adverse events?

.....

B3. Managing immune related adverse events: focus on skin and endocrine system

- Treating skin toxicity as a way to tackle quality of life
- Complex skin toxicity should be treated in collaboration with dermatologists and anatomopathologists
- Hypophysitis should always be considered and well explored in case of unexplained fatigue

MLTBE1903908-09 - 10/2019

Register now

IMMUNOTHERAPY: MANAGING THE BREAKTHROUGH

HOT TOPICS AND MULTIDISCIPLINARY CHALLENGES IN TODAY'S CANCER PATIENT CARE

MEETING



*A unique multidisciplinary educational
program providing information on
immunology and immunotherapies
to help improve patient outcomes*

The Academy Steering Committee



www.immunoscienceacademy.be



MLTBE1903908-09 - 10/2019

Supported by  Bristol-Myers Squibb

Register now